American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer.

By C. Azzoli, Sherman Baker, S. Temin, William Pao, Timothy B. Aliff, J. Brahmer, David H. Johnson, J. Laskin, G. Masters, D. Milton and 9 more. Journal of Clinical Oncology, 2009

936 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/24015e0a3e1658e3206b8989c99301f5c0e65ab1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. G. Masters
2. S. Temin
3. David H. Johnson
4. R. Marullo
5. E. Werner
6. N. Degtyareva
7. S. Ramalingam
8. B. Moore

Citations in the corpus

• Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. (2016, methodology): “Regarding cisplatin-based combinations, the trial reported by Scagliotti et al(68) was reviewed in the 2009 guideline.(1) It compared cisplatin plus gemcitabine with cisplatin plus pemetrexed and demonstrated improved OS for patients with adenocarcinoma treated with cisplatin plus pemetrexed (wherea”
• Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions (2013, methodology): “We used the non-small cell lung cancer cell line A549, as cisplatin-based chemotherapy is a standard of care for this type of tumor [37].”